Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 14/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | CCR2 | P41597 | 1/20 | 0.61 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17929345 | 0.86 | CXCR4 (0.56) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL898696 | 0.83 | ALDH1A1 (0.54) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL20806665 | 0.82 | CXCR4 (0.51) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL898695 | 0.80 | CXCR4 (0.74) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL25978396 | 0.80 | CXCR4 (0.48) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL674057 | 0.79 | CXCR4 (0.68) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL2489671 | 0.79 | CXCR4 (0.75) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL29823295 | 0.79 | CXCR4 (0.68) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL5611617 | 0.78 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL29490414 | 0.78 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206592-A1 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS BY INHIBITION OF CXCR4/CXCL12 SIGNALING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-07-21 | — | — | US | disclosed |
| US-20160206592-A1 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS BY INHIBITION OF CXCR4/CXCL12 SIGNALING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206592-A1 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS BY INHIBITION OF CXCR4/CXCL12 SIGNALING | CXCL12, GRM2, GRM1 | CXCR4 5/4885MEN1 4840/4885CHRM2 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.